Nurix Therapeutics second quarter 2026 report highlighted by a new $2.3 billion collaboration with Roche for its lead drug, bexobrutideg.

Nurix Therapeutics reported second quarter revenue of $9.0 million and a net loss of $0.81 per share. The quarter was defined by the announcement of a significant global collaboration agreement with Roche for its BTK degrader, bexobrutideg, which materially strengthens the company's balance sheet and validates its lead asset.

Key Highlights

• The company announced a global partnership with Roche for bexobrutideg, including an expected upfront payment of $700 million and potential total payments of up to $2.3 billion.
• Nurix ended the quarter with a cash position of $443.5 million, with pro-forma cash expected to be approximately $1.14 billion upon closing of the Roche deal.
• Updated clinical data for bexobrutideg in CLL patients demonstrated a high objective response rate (ORR) of 92.9% in a Phase 1b cohort of patients previously treated with a BTK inhibitor.